A patient of mine came in last fall, not for a consultation about his hip, but to ask me about peptides. He’d been injecting BPC-157 he ordered online for three months. No prescription. No oversight. No idea what he was actually putting in his body.

He wasn’t reckless. He was desperate. Chronic tendon pain, slow recovery, a body that wasn’t doing what it used to. He’d read the forums, watched the videos, and decided to act. I respected that instinct, even as I sat across from him calculating the risk he’d taken.

That conversation is happening everywhere right now. In clinics. In gyms. In group chats between people who are tired of feeling like their doctors have no answers. And most of the time, nobody is giving a straight answer.

I will.

The Biology Is Real. The Market Is Chaos.

Let me be clear about something first: peptides are not fringe science.

Insulin is a peptide. You know insulin. Semaglutide, the active compound in Ozempic and Wegovy, is a peptide. It just reshaped the global conversation about obesity. The FDA’s approval of the first oral semaglutide tablet for chronic weight management in late 2025 didn’t happen because molecules like this are unproven novelties. It happened because peptide biology, at the right end of the research spectrum, is some of the most precise and powerful pharmacology we have.

A peptide is a chain of amino acids, shorter than a protein, which makes it more targeted in function. These molecules act as biological messengers, instructing specific cells to perform specific tasks. Your body already produces thousands of them. The therapy argument is simple: can we supplement with synthetic versions to restore processes that slow with age or stress?

In some cases, yes. In many cases, we do not yet know. And that gap is where everything goes wrong.

Where the Science Ends and the Hype Begins

Here is the distinction that most of the wellness industry refuses to make clearly, so I will make it for you.

There are FDA-approved peptides with rigorous human trial data, clear mechanisms, and established safety profiles. Then there is a much larger category of peptides that are biologically plausible, show promising results in animal models, and are being injected by thousands of people with zero physician involvement, based on forum posts and influencer content.

Online peptide advertising increased 678% between 2022 and 2025 as GLP-1 drugs gave the entire category mainstream credibility by association.¹ If semaglutide, a peptide, could do what Ozempic does, the logic went, what else might these molecules be capable of? That halo effect drove enormous interest straight into the gray market, and straight into people’s bodies.

BPC-157 is the most visible example of what that looks like when it goes wrong. It is arguably the most popular peptide in the biohacking world. People are injecting it for tendon repair, gut health, and injury recovery. As of early 2026, **35 of 36 published BPC-157 studies are animal-only, sourced from a single lab with undisclosed conflicts of interest.**² The enthusiasm for this compound ran years ahead of the evidence. That is not a minor detail. That is the entire story.

The delivery problem compounds this. Most peptides break down in the digestive tract. Serious use cases require injection, which means sourcing, sterility, accurate dosing, and proper technique all become critical variables. When people are ordering compounds from gray-market vendors with no clinical oversight, every one of those variables is out of control.

The gap between “makes sense in theory” and “proven safe in humans” is vast. I have spent my career on the side of that gap that requires evidence before action. I am not moving.

The Regulatory Reckoning Was Inevitable

The FDA’s posture toward compounded peptides shifted hard in late 2023, and by 2025 it had become a full enforcement campaign. More than 50 warning letters issued to compounders, online sellers, and clinics. Criminal prosecutions. Raids on major gray-market vendors.

The DOJ forced Tailor Made Compounding LLC to forfeit $1.79 million, establishing that the federal government was willing to bring criminal charges, not just civil penalties.³ Peptide Sciences, one of the largest gray-market players, voluntarily shut down in March 2026 before the walls closed in.

The political dimension added one more layer. RFK Jr. publicly pushed the FDA to widen access, calling himself a fan of peptide treatments and signaling that roughly 14 peptides should be made more accessible through compounding pharmacies. The enforcement machine didn’t pause.

But what the political conversation did do, and this matters for everyone following this space, is force a legitimate question onto the table: should patients have a supervised, physician-guided pathway to promising compounds that sit outside the current approval framework?

That is a reasonable question. It deserves a serious answer. Not a gray market, and not a blanket ban.

The crackdown was necessary. Not because the underlying biology is fraudulent. But because access without oversight is not freedom. It is exposure.

What I Actually Believe

I am not here to bury peptides. I am here to be precise about them, because precision is what this conversation has been missing.

The legitimate end of this science is advancing fast. AI-assisted peptide design accelerated discovery pipelines dramatically in 2025. Cancer therapies, metabolic interventions, immune modulation, these are real frontiers with real rigor behind them. The biology deserves serious investment and serious research. And patients deserve physicians who are engaged with it, not dismissive of it.

Here is the framework I use for any emerging intervention, whether it is a peptide, a surgical technology, or a wellness protocol. It applies whether you are a clinician evaluating options or a patient trying to make a smart decision about your own body:

1. What is the evidence hierarchy? Human trials, animal models, and in-vitro data are not equivalent. Know which one you are standing on before you act.

2. Who is prescribing and who is sourcing? A compounding pharmacy with a physician-supervised protocol is not the same as a gray-market vendor and a self-injection tutorial.

3. What is the risk-benefit calculation for this specific person? Not the population. Not the forum. You, your biology, your context.

4. What is the baseline? No peptide, drug, or technology outperforms a life built on sleep, whole food nutrition, consistent movement, and stress management. That is not a platitude. It is the highest-leverage intervention available to every human being on this planet, and it costs nothing.

The Foundation Always Comes First

I have performed over 10,000 joint replacements. I have watched patients spend years treating symptoms that were the direct consequence of how they lived, how they ate, how much they slept, and how much they moved. And I have watched those same patients expect a molecule to fix what decades of lifestyle built.

It won’t.

The most powerful intervention in human health is still the one that requires the most discipline: prevention. Real food. Real sleep. Real movement. Real relationships. These are not soft suggestions. They are the clinical foundation without which medicine, including the most advanced peptide therapies, is always playing catch-up.

My patient who had been injecting BPC-157 for three months had never had a serious conversation with a physician about his diet, his sleep quality, or his inflammatory load. He went straight to the injection because it felt like action. I understand that impulse completely. People are tired of waiting for the system to give them better options.

But here is what I told him, and what I will say plainly here: action without a foundation is just noise.

If you are curious about peptides, that curiosity is legitimate. The biology is real. The potential is real. But find a physician who will engage with you seriously, demand to know where you are in the evidence hierarchy, and build the lifestyle foundation that makes any intervention actually work.

The shortcut culture that drove the gray market is the same culture that has people spending thousands of dollars on compounds while sleeping five hours a night and eating ultra-processed food.

The molecule is not going to save you from that. Nothing is.

The Bottom Line

We are in an era where the biology of human optimization is genuinely accelerating. The tools are getting more precise. The research is getting more sophisticated. Patients are more informed and more engaged than any generation before them. That is something to build on, not shut down.

The surgeon’s job, and every physician’s job, is to stand at the incision point: where intention meets reality, where the plan meets the patient in front of you. That means demanding evidence, providing real oversight, and being honest when the shortcut isn’t actually shorter.

The molecule is not the enemy. The shortcuts are.

Are you navigating peptide questions as a patient, a clinician, or both? I’d like to hear what you’re seeing, and what answers you’re still looking for.

Footnotes

1. PeptideExaminer, Online Peptide Market Growth Analysis, 2025.

2. STAT News / PeptideExaminer, BPC-157 Research Landscape Review, February 2026.

3. U.S. Department of Justice, United States v. Tailor Made Compounding LLC, 2025.

My patients don’t just come to me in pain.

They come to me exhausted. They come with type 2 diabetes, hypertension, and a knee that gave out, managing three chronic conditions at 55 that their parents didn’t have at 70.

They come having done, more or less, what they were told. They bought what was on the grocery shelf. They ate what was affordable. They fed their kids what was available at the school cafeteria and the drive-through and the gas station on the way home from work.

And somewhere in that chain of ordinary decisions, something went very wrong.

I trained at Mayo Clinic. I hold an engineering degree from Rose-Hulman. I have performed more than 10,000 joint replacements. I have sat on the boards of the largest orthopedic surgery organizations in the world. I see the consequences of the American food system in the operating room every single week.

What I see is not bad luck. It is not genetics. It is the predictable, documented, and entirely preventable result of a food supply that has been engineered for profit at the direct expense of human health, for decades, with the full knowledge of the people doing it.

I am done softening that statement.

What Is Actually In Your Food

American adults now get 53% of their daily calories from ultra-processed foods. For children, that number is 62%.[1] The CDC confirmed these figures in its first-ever report on the subject, published in August 2025. First-ever. We have known this was happening for years and the federal government only just got around to measuring it officially.

More than half your calories. Every day. From products that bear almost no resemblance to food in any meaningful biological sense.

I want to be specific, because “ultra-processed” is a term that lets the industry hide behind abstraction. Here is what it actually means: these are industrial formulations containing ingredients that did not exist in the human food supply until the 20th century and whose long-term biological effects were never independently verified before they were put in everything you eat.

Petroleum-derived synthetic dyes: Red No. 40, Yellow No. 5, Yellow No. 6, Blue No. 1. Added to thousands of products to make them visually appealing. Red No. 3, used for decades, was finally banned by the FDA in January 2025 after the agency’s own data showed it causes cancer in animals.[2] It took until 2025.

High-fructose corn syrup, engineered to be sweeter and cheaper than sugar, metabolized by the liver differently than naturally occurring sugars, and linked to fatty liver disease, insulin resistance, and obesity.[3]

Emulsifiers like carrageenan and polysorbate 80, added to improve texture and shelf life, with emerging research suggesting they disrupt gut microbiome integrity and promote systemic inflammation.[4]

Artificial preservatives including BHA and BHT, added to prevent oxidation in packaged foods, classified as reasonably anticipated human carcinogens by the National Toxicology Program.[5]

Partially hydrogenated oils and industrial trans fats, so thoroughly documented as cardiovascular poison that the FDA banned them in 2018, but not before decades of consumption drove heart disease rates that still haven’t fully recovered.[6]

And over 1,000 other ingredients added to the food supply under the FDA’s “Generally Recognized As Safe” program, GRAS, in which food companies are permitted to certify the safety of their own ingredients without notifying the FDA or the public.[7] The MAHA Commission has specifically targeted this loophole for reform, and they are right to do so. An industry self-certifying its own ingredients as safe is not a regulatory system. It is an honor system operating inside a profit motive.

I agree with the core food agenda that Secretary Kennedy and the Make America Healthy Again movement have put on the national table: petroleum-based dyes should come out of the food supply, GRAS loopholes should be closed, ultra-processed food should be defined at the federal level, and SNAP benefits should not fund products with zero nutritional value. These are not partisan positions. They are basic public health positions backed by overwhelming evidence.

What It Is Doing to Your Body

The research on this is no longer at the frontier. It is settled, repeated, and alarming.

A 2024 umbrella review in The BMJ, covering 45 meta-analyses and nearly 10 million study participants, found convincing evidence that a diet high in ultra-processed foods increases the risk of death from cardiovascular disease by 50%.[8] Highly suggestive evidence placed the increased risk of obesity at 55%, Type 2 diabetes at 40%, and death from heart disease at 66%.[8]

The American Heart Association’s own 2025 Science Advisory confirmed that high versus low intake of ultra-processed foods is linked to a 25% to 58% higher risk of cardiometabolic outcomes and a 21% to 66% higher risk of mortality.[9]

Every additional 100 grams per day of ultra-processed food consumption is associated with a 14.5% higher risk of hypertension, a 5.9% increased risk of cardiovascular events, and a 19.5% higher risk of digestive diseases.[10]

These are not small signals. These are population-level findings, replicated across dozens of independent studies on tens of millions of people, in peer-reviewed journals at the highest level of evidence medicine produces.

The result, in real terms: more than 2 in 5 American adults now have obesity.[11] Treating diabetes and prediabetes costs this country over $327 billion annually.[12] Obesity-related medical care runs nearly $173 billion per year.[11] Ninety percent of all U.S. healthcare spending goes toward people with chronic and mental health conditions, most of them diet-related.[13]

The CDC projects that chronic disease will cost the United States $47 trillion between now and 2039.[14]

I’ll say that again. Forty-seven trillion dollars. Over the next 15 years. Driven in enormous part by conditions that trace directly to what is being sold at every grocery store, fast food counter, vending machine, and school cafeteria in America.

The Synthetic Dye Problem Is Bigger Than You Think

I want to spend a moment on food dyes specifically, because this is where the policy fight is most visible right now and where the industry’s behavior has been most egregious.

The synthetic dyes currently in the American food supply are petroleum derivatives. They are banned or heavily restricted in the United Kingdom, the European Union, Japan, and Australia, where products containing them must carry warning labels stating that the food “may have an adverse effect on activity and attention in children.”[15] In the U.S., they carry no warning. They are in children’s cereals, fruit snacks, sports drinks, candies, macaroni and cheese, and thousands of other products specifically marketed to children.

In 2025, roughly 75 bills targeting food dyes were introduced in 37 states.[16] West Virginia banned Red No. 40, Yellow No. 5, and Yellow No. 6 by law. California had already moved on four additives. Nestlé, Hershey, and PepsiCo pledged to begin removing synthetic colors voluntarily. The Consumer Brands Association asked its members to eliminate federally certified artificial dyes from products by end of 2027.[16]

The industry did not do this because they suddenly grew a conscience. They did it because the political pressure finally became unavoidable. These ingredients have been known to carry risk for decades. They stayed in the food supply because removing them cost money.

That calculation, what is profitable versus what is safe, is the operating logic of the entire ultra-processed food system. It has been from the beginning.

The Loop Nobody Talks About

Here is the part that should make you the most angry.

The food industry spends hundreds of millions of dollars every year lobbying against nutritional labeling requirements, sugar taxes, marketing restrictions to children, and front-of-pack warning labels.[17] They fund nutrition research designed to produce favorable conclusions. They helped shape decades of USDA dietary guidelines. They fought trans fat restrictions for years after the science was clear.

And when the chronic disease epidemic their products helped create shows up in your body, the hospital system is there to treat it. At $26,993 per year in employer-sponsored insurance premiums.[18] With a deductible that has gone up every year.[19] With an insurance company that will spend the next 90 days deciding whether your treatment is approved.

The food industry makes you sick. The healthcare industry charges you to manage it. Neither has a financial incentive for you to be well.

I am not speculating about this. I am describing the system as it functions, from inside it.

What I See in the Operating Room

I operate on patients whose joints have been destroyed in part by the inflammatory burden of decades of ultra-processed food consumption. I see the metabolic consequences, the effects of chronic systemic inflammation, the tissue changes that come from bodies running on ingredients they were never designed to process, every week.

These are not people who made bad choices. These are people who ate the food that was available, affordable, and relentlessly marketed to them by an industry that knew, and put the profit calculation ahead of the public health consequence.

I want fewer patients in my operating room, not more. The only path to that is a food supply that stops manufacturing the chronic disease that fills it.

What You Can Do Right Now

Read the ingredient label, not the nutrition facts panel. The nutrition facts panel is what the industry wants you to look at. Calories, fat grams, and protein are distractions. The ingredient list is where the truth is. If it contains synthetic dyes, HFCS, partially hydrogenated anything, or additives you cannot trace to a whole food source, that product is a bet against your long-term health.

Cook whole food when you can. Not as a lifestyle aspiration. As a defensive act. The data on what ultra-processed food does to your cardiovascular system, your metabolic health, and your mortality risk is overwhelming.

Support the food policy reforms that are actually grounded in evidence: mandatory front-of-pack warning labels, closure of the GRAS self-certification loophole, removal of petroleum-derived dyes from the food supply, and restrictions on ultra-processed food marketing to children. These are not radical positions. They are the standard in most of the developed world.

And when the food industry tells you their product is part of a balanced diet, ask who paid for that research.

Why I’m Writing This

I am inside the machine. I see both the food system’s consequences and the healthcare system’s response to them, up close, every week. Most people with the standing to speak about this from the inside have financial relationships that keep them quiet.

I don’t.

The Incision Point exists because the American public deserves a straight account of what is actually happening to their health, who is responsible, and what can actually change it. Not from a commentator. From a physician who is operating on the results.

Subscribe if you want to keep reading. Share this if it made you angry enough to want someone else to see it.

That anger is appropriate. Use it.

What ingredient on a food label has surprised or disturbed you most? Drop it in the comments.

Footnotes

1. CDC/NCHS Data Brief No. 536, August 2025. “Ultra-Processed Food Consumption Among U.S. Children and Adults, August 2021-August 2023.” cdc.gov

2. FDA, “FDA Revokes Authorization for the Use of Red No. 3 in Food and Ingested Drugs,” January 2025. fda.gov

3. Multiple sources including NIH research on fructose metabolism and fatty liver disease; Stanhope KL et al., multiple publications on high-fructose corn syrup and metabolic outcomes.

4. Chassaing B et al. “Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome.” Nature. 2015;519:92-96. Subsequent human studies have supported the association.

5. National Toxicology Program, U.S. Department of Health and Human Services. Report on Carcinogens listings for BHA and BHT.

6. FDA, “Final Determination Regarding Partially Hydrogenated Oils,” 2018. fda.gov

7. MAHA Commission Assessment, May 2025; ABC News reporting on GRAS reform proposals, September 2025.

8. Lane MM et al. “Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses.” BMJ. 2024;384:e077310. doi:10.1136/bmj-2023-077310

9. American Heart Association Science Advisory, 2025. newsroom.heart.org

10. American College of Cardiology analysis of systematic review data, May 2025. acc.org

11. CDC, “Fast Facts: Health and Economic Costs of Chronic Conditions,” August 2025. cdc.gov

12. American Diabetes Association, cost of diabetes data, cited 2025.

13. CDC, “Health and Economic Costs of Chronic Diseases.” cdc.gov

14. Partnership to Fight Chronic Disease/GlobalData. December 2025. fightchronicdisease.org

15. European Food Safety Authority assessments of synthetic food dyes; UK Food Standards Agency labeling requirements.

16. KFF Health News, “RFK Jr.’s MAHA Movement Has Picked Up Steam in Statehouses,” January 13, 2026. kffhealthnews.org

17. Multiple lobbying expenditure analyses cited in Ballard Brief, BYU, “The Overconsumption of Ultra-Processed Foods in the United States,” 2024.

18. KFF 2025 Employer Health Benefits Survey, October 2025. doi:10.1377/hlthaff.2025.01106

19. KFF Health News, “A New Car vs. Health Insurance? Average Family Job-Based Coverage Hits $27K,” October 2025.

Editorial note on seed oils: The research on isolated seed oil consumption is genuinely contested, with the mainstream peer-reviewed consensus, including 2025 findings from Johns Hopkins, the American Heart Association, and multiple meta-analyses, finding that linoleic acid in seed oils is not the independent driver of inflammation or cardiovascular disease that MAHA messaging claims. The article frames seed oils as one industrially deployed ingredient within the broader ultra-processed food system, which is the scientifically defensible position.

I do not learn about my patients from their charts.

I learn about them from their tissue.

After 10,000+ joint replacements, I can tell within the first few minutes of a case what kind of physical life someone has been living. The quality of the muscle surrounding the joint. The integrity of the supporting structures. The biological age of the architecture I am working inside — which is often dramatically different from the number on the patient’s wristband.

Two patients last year. Similar age. Similar diagnosis. Similar preoperative pain scores. Completely different bodies on the table.

The first was strong. Not a competitive athlete — just someone who had lifted consistently for years, maintained their muscle mass, kept their posture upright and their supporting structures intact. The surgery was clean. Recovery was textbook. They were walking without assistance faster than the protocol predicted.

The second had spent a decade doing what most Americans do for fitness — some walking, occasional cardio, nothing that loaded the skeletal muscle with any real demand. The muscle surrounding the joint was atrophied and soft. The supporting architecture was compromised. The surgery was harder. Recovery was slower. The complications were not dramatic, but they were real, and they were predictable.

Same diagnosis. Same surgeon. Completely different outcomes.

The difference was muscle. And nobody had ever told the second patient that muscle was something they needed to deliberately build and protect.

That failure is not the patient’s fault. It is the system’s.

The Silent Epidemic Nobody Is Screening For

Sarcopenia — the progressive loss of skeletal muscle mass and function — is one of the most consequential and least discussed health crises in American medicine.

After age 30, the average adult loses between 3 and 8 percent of muscle mass per decade without deliberate intervention. After 60, that rate accelerates. By the time most people arrive at my operating table in their sixties and seventies, they have been losing muscle for three decades and have never once had a physician discuss it with them, screen for it, or prescribe anything to address it.

The downstream consequences are not limited to surgical outcomes. A 2022 meta-analysis published in the Journal of Cachexia, Sarcopenia and Muscle examining data from over 700,000 individuals found that low muscle mass is independently associated with all-cause mortality, cardiovascular mortality, and metabolic disease — with effect sizes comparable to established risk factors like hypertension and dyslipidemia.

Low muscle mass is as dangerous as high blood pressure. We screen aggressively for one. We do almost nothing about the other.

The annual physical does not measure muscle mass. It does not assess grip strength — one of the most validated predictors of long-term mortality in the literature. It does not ask about resistance training. It measures weight, which tells you almost nothing useful about the composition of that weight or the biological function of the body carrying it.

A scale weight is not a health metric. Muscle mass is.

The Cardio Lie We Have Been Living

I want to challenge something that has been accepted as health gospel for forty years.

The dominant fitness narrative in America — the one that produced a generation of recreational runners, spin class devotees, and elliptical machine regulars — is built almost entirely around cardiovascular exercise. Cardio for heart health. Cardio for weight loss. Cardio as the primary currency of physical fitness.

Cardiovascular exercise has real and documented benefits. I am not dismissing it.

But cardio does not build muscle. And muscle, it turns out, is not optional.

The cultural over-indexing on cardio has produced millions of metabolically fragile people who are aerobically functional but structurally deficient — people whose hearts are reasonably conditioned but whose skeletal muscle is insufficient to protect their joints, regulate their metabolism, or sustain them through a major medical event.

I see them on my table regularly. Thin, aerobically active, and sarcopenic. The combination is more common than most people realize, and it is more dangerous than simple obesity in certain surgical contexts because it carries none of the visible warning signs that trigger clinical concern.

The engineering problem here is straightforward: you cannot maintain a structure without loading it. A joint unsupported by adequate muscle is a joint under accelerated mechanical stress. A skeleton not subjected to regular resistance load loses density. A body that only moves through low-resistance, repetitive motion patterns develops the postural adaptations of exactly the lifestyle it is living.

Sitting is a structural problem as much as a metabolic one. The anterior pelvic tilt, the forward head posture, the shortened hip flexors and inhibited glutes that characterize a desk-bound population — these are not cosmetic issues. They are mechanical loading problems that alter joint stress patterns and accelerate the degenerative cascade I am eventually asked to surgically address.

The body adapts to the demands placed on it. If the demand is eight hours of sitting and thirty minutes of walking, the body optimizes for exactly that. It does not maintain architecture it is not being asked to use.

What Muscle Actually Does

Here is the piece the cardio-only conversation misses entirely.

Skeletal muscle is not simply a mechanical system for moving the body. It is an endocrine organ — one of the largest in the body — that produces and secretes signaling molecules called myokines in direct response to mechanical load.

Myokines regulate systemic inflammation, glucose metabolism, cognitive function, immune response, and fat oxidation. IL-6 released from contracting muscle during resistance exercise has potent anti-inflammatory effects — the same cytokine that drives pathology when chronically elevated by stress and poor diet becomes protective when acutely released through muscular contraction.

Irisin, a myokine released during resistance training, crosses the blood-brain barrier and has been associated in multiple studies with reduced neurodegeneration and improved cognitive function. BDNF — brain-derived neurotrophic factor — is upregulated by resistance exercise and represents one of the most powerful known stimulants of neuroplasticity.

When you lift, you are not just building muscle. You are running an anti-inflammatory protocol, a metabolic optimization program, and a cognitive enhancement intervention simultaneously.

There is no drug that does all of that. There is no supplement that replicates it. There is only load.

The Framework: Muscle First

I want to give you something concrete to carry out of this article.

1. Reframe the goal. The objective of exercise is not weight loss or cardiovascular fitness. Those are byproducts. The primary objective is building and maintaining skeletal muscle mass throughout your lifespan. Every other benefit follows from that.

2. Resistance training is non-negotiable. Two to three sessions per week of progressive resistance training — exercises that place genuine mechanical demand on major muscle groups — is the minimum effective dose. Not yoga. Not walking. Not the light resistance band routine. Load. Progressive, deliberate, increasing over time.

3. Protein supports the structure. Muscle protein synthesis requires adequate dietary protein. The RDA of 0.8g per kilogram of body weight was established to prevent deficiency, not to optimize muscle maintenance in aging adults. The sports medicine and longevity literature consistently supports 1.6 to 2.2g per kilogram for anyone over 40 who is training with intent.

4. Posture is structural integrity. If you sit for more than six hours a day, your hip flexors are shortened, your glutes are inhibited, and your spine is loaded in a pattern it was not designed to sustain indefinitely. Address this deliberately — not with stretching alone, but with the resistance training that restores the posterior chain function that sitting systematically dismantles.

5. Start now, not later. The research on resistance training benefits in adults over 60, 70, and even 80 is unambiguous — it is never too late to build meaningful muscle and recover meaningful function. But the earlier you start, the more you are protecting rather than rebuilding.

The Prescription We Are Not Writing

I am a surgeon. I fix joints that have failed. I am good at it, and I will keep doing it.

But the most important intervention I can offer most of my patients is not the surgery. It is the conversation I try to have before surgery becomes necessary — the one about what their body needs to stay out of my operating room.

Muscle is medicine. It is the most powerful preventive intervention available for joint disease, metabolic disease, cognitive decline, and all-cause mortality. It is free, it is accessible, and it requires no prescription.

We are not prescribing it. We are not screening for its absence. We are not teaching it in medical school with anything close to the emphasis the evidence demands.

That needs to change. And it starts with surgeons — who see the consequences more clearly than almost anyone — leading that conversation rather than waiting for the system to have it.

Build the muscle. Protect the structure. Do not wait until someone like me is the next appointment on your calendar.

That is the incision point.

Are you lifting? Or are you still in the cardio trap?

Tell me where you are… and what is stopping you from changing it.

Dr. Michael Meneghini

I have looked inside more than 10,000 human joints.

I can tell you things about the human body that do not show up in textbooks. I can tell you what a life of chronic stress looks like in synovial tissue. I can tell you the difference between a joint that has been quietly inflamed for a decade and one that has not.

What I see more than anything else, in patient after patient, year after year, is the same thing.

Inflammation. Systemic, chronic, low-grade, and almost entirely invisible until it is not.

The frustrating part is not that this is happening. The frustrating part is that we have the tools to detect it early, the knowledge to address it directly, and a medical system that has organized itself almost perfectly to do neither.

I know this because I almost missed it in myself.

The Silent Driver Nobody Is Naming

Chronic low-grade inflammation is the common upstream driver of the four leading causes of death in America — cardiovascular disease, cancer, diabetes, and Alzheimer’s disease.

Not a contributing factor. The upstream driver.

A landmark analysis published in Nature Medicine in 2023 examined data from nearly 45 million patients and concluded that chronic inflammation is implicated in more than 50% of all deaths globally. The inflammatory cytokine interleukin-6, elevated C-reactive protein, and chronic activation of the NF-kB signaling pathway appear across the pathology of heart disease, type 2 diabetes, multiple cancers, and neurodegenerative disease with a consistency that is no longer scientifically debatable.

We are not talking about the acute inflammation that heals a wound. That version is one of the most elegant systems in biology. We are talking about its chronic, dysregulated cousin — the kind that never fully switches off, that quietly degrades tissue over years and decades, that shows up in your bloodwork as a whisper long before it announces itself as a diagnosis.

Your annual physical is almost certainly not testing for it.

What the OR Taught Me

I started noticing a pattern years into my surgical career.

Two patients, similar age, similar weight, similar preoperative function scores. I open the first joint and the tissue is relatively healthy. I open the second and it is a different story entirely — inflamed synovium, degraded tissue quality, a joint that looks biologically a decade older than the chart suggests.

The difference was not always explainable by diagnosis alone. It was systemic.

I started asking more questions. Diet. Sleep. Stress. Movement. The answers were predictable in their consistency. Then I ran my own labs — and found markers I did not expect in someone performing, by every external measure, at a high level.

That was the moment I understood this personally, not just clinically.

The association between systemic inflammation and poor surgical outcomes is well-documented. Elevated preoperative CRP is an independent predictor of complications after joint replacement. Metabolic syndrome substantially increases infection risk, wound complication rates, and implant failure. I was seeing the end stage of a process that had started silently, years earlier, that nobody had ever named for these patients.

The System Is Built to Miss It

We are organized to treat disease, not to prevent it. And chronic inflammation sits in the gap between the two.

Your annual physical screens for acute illness and manages established diagnoses. It is a liability screen dressed up as a health assessment — almost entirely backward-looking. It identifies what has already gone wrong, not what is quietly accumulating.

High-sensitivity CRP — the most accessible and clinically validated marker of systemic inflammation — is not standard on most wellness panels. It costs a few dollars to run. The JUPITER trial, published in the New England Journal of Medicine in 2008, enrolled nearly 18,000 patients with normal LDL but elevated hsCRP and demonstrated that treating the inflammatory burden reduced cardiovascular events significantly.

That was 2008. Seventeen years ago. hsCRP is still not standard of care.

The system is not failing by accident. Prevention does not bill. Chronic disease management does. That is not cynicism. That is an incentive structure.

And then there is the NSAID problem.

Americans consume approximately 30 billion doses of NSAIDs annually. They are the default response to the pain and stiffness that chronic inflammation produces. They do not address inflammation. They suppress its signal.

Long-term NSAID use carries documented risks. A 2017 meta-analysis in the British Medical Journal examining more than 446,000 patients found that all common NSAIDs were associated with significantly elevated risk of acute myocardial infarction — with risk emerging within the first week of use.

We are managing the signal of chronic inflammation with a drug class that, at population scale, is generating its own cardiovascular burden. This is what symptom suppression without root cause resolution looks like in practice.

Two Things You Can Do This Week

Ask for hsCRP on your next blood panel.

It is inexpensive, widely available, and requires no special preparation. Optimal is below 1.0 mg/L. Above 2.0 mg/L represents elevated cardiovascular risk. Above 3.0 mg/L is high risk. If you are above 2.0 and nobody has discussed it with you, you are in the gap the system is not designed to address. While you are at it, ask for homocysteine — independently associated with cardiovascular disease, cognitive decline, and systemic inflammatory burden. Both tests together cost less than a co-pay.

Remove the fuel.

Chronic inflammation has inputs. The most powerful modifiable ones, ranked by the strength of the evidence: diet first — ultra-processed food, refined seed oils, and added sugar directly drive the NF-kB inflammatory pathway. Sleep second — a single night of poor sleep measurably elevates IL-6 and TNF-alpha. Movement third — resistance training specifically produces anti-inflammatory myokines through skeletal muscle; a sedentary body is an inflamed body. Chronic stress fourth — sustained cortisol elevation drives inflammatory gene expression, documented in the psychoneuroimmunology literature for thirty years.

None of these require a prescription. None generate revenue for the sick-care system. All of them work.

Treat the Root, Not the Branch

Every chronic disease conversation you will have with a doctor is a branch conversation. Statins for cholesterol. Metformin for blood sugar. NSAIDs for joint pain. Clinically appropriate in many contexts. Entirely silent on the root.

The root is inflammation.

The branch conversations are not wrong. They are incomplete. And incomplete, at population scale, over decades, is how you end up with a country where chronic disease is the norm and the healthcare system calls it inevitable aging.

It is not inevitable. Ask for the test. Change the inputs. Have the root conversation.

That is the incision point.

What markers is your doctor running? AND, what’s missing from your panel?

Tell me below.

Dr. Michael Meneghini

Total knee arthroplasty (TKA) continues to be a widely successful procedure by alleviating pain and restoring function for patients with degenerative disease of the knee. However, a significant number of patients continue to be dissatisfied with their TKA. Although patient dissatisfaction is multifactorial, the inability of total knee implants to restore native knee kinematics is likely a contributing factor.

Historically, the orthopedic world has debated between two main camps of knee design: posterior-stabilized and cruciate-retaining. Traditional posterior-stabilized total knee implant designs use a cam and post mechanism, which promotes roll back of the femur on the tibia during knee flexion. In contrast, traditional cruciate-retaining knee implants have a round-on-flat articulation that relies on an intact posterior cruciate ligament (PCL).

Read more

My patients are always asking me where their money goes.

Not about their diagnosis. Not about recovery time. The first question, more often than I’d like to admit, is some version of: “Doctor, what is this going to cost me?”

These are working people. People with jobs, with insurance cards in their wallets, with coverage they’ve paid into for years. And they are terrified of the bill that comes after I help them.

That fear is not irrational. That fear is the correct response to a system that has been taking their money for decades and delivering less every year in return. I’ve watched it happen from inside the operating room, inside the boardroom, and inside the data. And I’m done staying quiet about it.

The Number They Don’t Put on the Benefits Brochure

The average American family with employer-sponsored health insurance is now paying $26,993 per year in premiums.[1] Just premiums. Before you’ve seen a single doctor. Before you’ve filled a single prescription.

Your employer pays the bigger share of that. But your portion comes out of your paycheck every two weeks, quietly, before you ever see it. And then, when you actually need care, you pay again. Deductibles. Copays. Coinsurance. Out-of-network surprise bills that arrive two months after a procedure you thought was covered.

Add it all up: a family of four with “good” employer insurance is carrying nearly $29,000 in total annual healthcare costs.[2]

More than most Americans spend on housing.

And it has gone up 6% or more, every single year, for three years running.[3] Not because the care is getting better. Not because the outcomes are improving. Because the entities that control your access to care have spent decades making sure there is nowhere else to go.

Here Is What Is Actually Happening to Your Money

I need you to understand this part clearly, because the people profiting from your confusion are counting on it staying confusing.

When you go to a hospital for a procedure, you are not just paying your surgeon. You are paying a facility fee. That fee goes to the hospital itself. And because hospital systems have spent the last 20 years buying up every competing practice, clinic, and surgery center in their market, there is increasingly nowhere else to go.

In 2023, one or two hospital systems controlled all commercial inpatient care in roughly half of all U.S. metropolitan areas.[4] Half the country. One or two choices. When competition disappears, prices go one direction.

Your insurer is not fighting this on your behalf. They negotiated contracts with those same hospital systems years ago. The terms are confidential. The prices are hidden. And when costs rise faster than they can absorb, their move is not to push back on the hospital. Their move is to raise your deductible, narrow your network, and deny more of your claims.

None of that reduces what the hospital charges. It just moves more of the bill directly onto you.

This is not an accident. It is not incompetence. It is a business model running exactly as designed.

The Doctor in That Room Isn’t Getting Rich Either

I want to say something that surprises most people.

Physician compensation, adjusted for inflation, has declined significantly over the past two decades, even as premiums have exploded.[5] The average doctor today spends nearly as much time on insurance paperwork and prior authorization battles as on patient care.[6]

Burnout among American physicians is approaching 50%. Not because doctors stopped caring. Because the system converted them into billing units inside someone else’s revenue machine.

I’ve been that doctor. I trained at Mayo Clinic. I have an engineering degree from Rose-Hulman. I have performed more than 10,000 joint replacements. And I have sat in boardrooms in my scrubs listening to hospital executives discuss “margin optimization” while my patients asked me what their surgery was going to cost them.

At a certain point, you stop rearranging the chairs.

I left. I built Indiana Orthopedic Institute from two people to more than 100 employees and 16 surgeons in three years, physician-owned, patient-first, transparent on cost. Not because I had a brilliant business idea. Because patients and employers found us, saw what care could actually look like, and refused to go back to the alternative.

That tells you everything about how hungry people are for something different.

The Lower-Cost Option Exists. You Just Don’t Know About It.

This is the part that makes me the most frustrated. Because the solution isn’t theoretical. It is operating right now, in thousands of locations across the country, and most patients have no idea.

Ambulatory surgery centers, or ASCs, are physician-owned outpatient surgical facilities. For most elective procedures, including the joint replacements I perform every week, the clinical outcomes are equivalent to hospital-based care.

The cost is not.

The same procedure in an ASC costs less than half of what it costs in a hospital outpatient department.[7] Medicare alone saves an estimated $4.2 billion every year by routing surgeries to ASCs instead of hospitals.[7] Patients save an average of $684 per procedure, out of pocket, just by changing the location of their care.

Some employers have figured this out. They are now contracting directly with physician-owned surgery centers, sending their employees in for procedures, waiving all out-of-pocket costs, and still coming out ahead financially compared to what their insurance network would have charged at the local hospital.[8]

The employer pays for the flight. Pays for the hotel. Covers every dollar of the procedure. And still saves money.

That gap between what the hospital charges and what a physician-owned facility charges is not a small inefficiency. It is the size of the lie the system has been telling you.

Why I’m Writing This

I am a surgeon. I fix broken things.

The American healthcare system is broken in ways that are specific, documented, and solvable. And the people most harmed by it, the families watching their paychecks erode, the patients who delay care because they cannot predict the bill, the workers who technically have insurance and still end up in medical debt, are also the people who have been given the least access to a straight explanation of what is actually happening.

That is what I’m here to change.

I am not a policy analyst. I am not a commentator watching this from a distance. I am inside the machine, every single week, seeing the consequences of these decisions in the people who come to me in pain and leave scared about the bill. That proximity gives me something most healthcare writers don’t have: I know exactly where the bodies are buried, and I have nothing to lose by saying so.

If you want the unfiltered version of what is actually happening in American healthcare, subscribe. Every piece I write is grounded in clinical data, operational experience, and the kind of specificity you don’t get from people who have never stood at an operating table or walked out of a hospital boardroom furious.

If this article made you angry, share it. The system counts on your frustration staying private. Make it loud.

And if you have a healthcare bill sitting on your kitchen table right now that you don’t understand, drop a comment below. I read every one. You deserve a straight answer.

Thanks for reading.

Dr. Michael Meneghini

What is the most absurd medical bill you’ve ever received? I want to know.

Footnotes

1. KFF 2025 Employer Health Benefits Survey, October 22, 2025. Wager E et al. Health Benefits in 2025: Family Premiums Rise 6 Percent. Health Affairs. doi:10.1377/hlthaff.2025.01106

2. Peterson-KFF Health System Tracker, “How Much Do People with Employer Plans Spend Out-of-Pocket on Cost-Sharing?” February 2026. healthsystemtracker.org. Note: total figure based on 2024 premium and out-of-pocket data; 2025 total will be higher given the 6% premium increase.

3. KFF Health News, “A New Car vs. Health Insurance? Average Family Job-Based Coverage Hits $27K,” October 28, 2025. kffhealthnews.org

4. Peterson-KFF Health System Tracker, “Eight Trends Shaping 2026 Healthcare Costs,” March 2026. healthsystemtracker.org

5. Physician compensation trend data. Note: the directional decline is well-documented across multiple sources including Merritt Hawkins and the Physician Advocacy Institute. Recommend substituting a personal data point or a specific sourced figure before final publication.

6. Arndt BG et al. “Tethered to the EHR: Primary Care Physician Workload Assessment Using EHR Event Log Data and Time-Motion Observations.” Annals of Family Medicine, 2017. Directionally consistent with more recent analyses; recommend updating citation if a more recent source is available.

7. Ambulatory Surgery Center Association (ASCA)/KNG Health Consulting, Medicare cost savings analysis; Colliers Q3 2025 Healthcare Services Report, via Healthcare Finance News, October 2025.

8. ASC News, “Top Ambulatory Surgery Center Trends for 2025,” January 2025, citing Surgery Center of Oklahoma. ascnews.com

Unicompartmental knee arthroplasty (UKA), or partial knee replacement, is a technically demanding procedure vulnerable to errors in component positioning, alignment, and soft-tissue balancing. Early failures have been linked to excessive posterior tibial slope and placement of tibial components in a high degree of varus. To address these vulnerabilities, robotics has been marketed and increasingly adopted.

The orthopedic community has been inundated with messaging suggesting that robotic-assisted UKA improves the accuracy and precision of bone preparation and component alignment. But this technology comes at a steep price. Initial capital investment for robotic arthroplasty systems is estimated to range from $800,000 to $1,200,000, and disposable costs are estimated to range from $750 to $1,000 per case. In an era where reducing healthcare costs is paramount, we have to ask: Does everyone need a million-dollar robot, or does surgical experience still matter?

Read more

Despite the clinical success of primary total knee arthroplasty (TKA), complications requiring revision TKA (rTKA) persist. Treatment goals in rTKA are to perform a durable reconstruction that alleviates a patient’s pain and improves function. In rTKA, joint line elevation may occur when bone lost from the distal femur is not replaced, leading to historical recommendations that distal femoral augments be used to restore a native joint line.

The consequences of an elevated joint line were postulated to be inferior patient outcomes, decreased range of motion, less extensor strength, and anterior knee pain. However, interestingly, many “symptoms” of an elevated joint line can also be explained by instability, which has recently been described as one of the leading reasons for additional revisions of rTKAs. This study’s purpose was to evaluate the effect of joint line height elevation on validated patient-reported outcome measures (PROMs) using modern revision implants.

Read more

Despite the clinical success of primary total knee arthroplasty (TKA), complications requiring revision TKA (rTKA) persist. Treatment goals in rTKA are to perform a durable reconstruction that alleviates a patient’s pain and improves function. In rTKA, joint line elevation may occur when bone lost from the distal femur is not replaced, leading to historical recommendations that distal femoral augments be used to restore a native joint line.

The consequences of an elevated joint line were postulated to be inferior patient outcomes, decreased range of motion, less extensor strength, and anterior knee pain. However, interestingly, many “symptoms” of an elevated joint line can also be explained by instability, which has recently been described as one of the leading reasons for additional revisions of rTKAs. This study’s purpose was to evaluate the effect of joint line height elevation on validated patient-reported outcome measures (PROMs) using modern revision implants.

Read more

Despite the clinical success of primary total knee arthroplasty (TKA), complications requiring revision TKA (rTKA) persist. Treatment goals in rTKA are to perform a durable reconstruction that alleviates a patient’s pain and improves function. In rTKA, joint line elevation may occur when bone lost from the distal femur is not replaced, leading to historical recommendations that distal femoral augments be used to restore a native joint line.

The consequences of an elevated joint line were postulated to be inferior patient outcomes, decreased range of motion, less extensor strength, and anterior knee pain. However, interestingly, many “symptoms” of an elevated joint line can also be explained by instability, which has recently been described as one of the leading reasons for additional revisions of rTKAs. This study’s purpose was to evaluate the effect of joint line height elevation on validated patient-reported outcome measures (PROMs) using modern revision implants.

Read more

Dislocation remains a challenging and relatively common complication following total hip arthroplasty (THA). Instability is the leading cause of revision following THA, which can lead to poor patient outcomes and increased economic burden. To combat this, surgeon-controlled factors for the prevention and treatment of instability often include maximizing femoral head diameter and the use of dual mobility (DM) bearings.

DM femoral head bearings were approved for use in the United States in 2009. The use of this implant design has grown significantly over the last decade and is now commonly used in modern THA for both primary and revision cases. The DM design combines the low frictional torque principle of a smaller head size with the benefit of a large-diameter outer bearing to increase the head-neck ratio. However, it remains unclear from the literature what benefit DM provides compared to simply using large-diameter femoral heads. We wanted to find out if the complex, heavily marketed DM bearing was actually better than a traditional “jumbo” head of the same size.

Read more

Healthcare is now an $11 trillion global industry.

That number is projected to reach $21 trillion by 2030 - a compound annual growth rate (CAGR) of roughly 7%.

Let me put that in perspective. That is a similar growth rate to semiconductor chips and Apple Inc.. Healthcare is growing faster than most technology sectors, and we are not curing anything or inventing something new. We are managing disease. We are keeping people alive, sick, and returning - year after year - to a system that profits from their continued illness.

That is not healthcare. That is the healthcare industry. And there is a profound difference.

We Are Not Curing Anything

The two primary drivers of this explosive growth are an aging population and the rising prevalence of chronic disease.

Diabetes. Obesity. Cardiovascular disease. Osteoarthritis. Conditions that, in many cases, are directly traceable to lifestyle - to processed food, physical inactivity, poor sleep, and chronic stress. These are not mysteries. The science is settled.

The global population aged 65 and older is projected to reach 1.5 billion in the coming decades, and healthcare spending on this age group alone is expected to exceed $1.2 trillion.¹ That is a staggering number. But here is the question no one in the healthcare industry wants to answer honestly: how much of that spending is curative versus palliative?

Very little of it is curative.

We are not winning the war on chronic disease. We are funding its perpetual management. The pharmaceutical companies are not incentivized to cure diabetes - they are incentivized to sell insulin, GLP-1 agonists, and metformin for the next 50 years. The hospital systems are not incentivized to keep patients away - they are incentivized to fill beds, generate readmissions, and maximize billing codes.

The business model of American healthcare is predicated on sick people staying sick.

I do not say that as a conspiracy theory. I say it as someone who has operated inside this machine for 20+ years.

The Trillion-Dollar Waste Machine

Here is what the system will not advertise: a landmark study published in JAMA estimated the annual cost of waste in the US healthcare system at between $760 billion and $935 billion - approximately 25% of total healthcare spending.²

A quarter of everything we spend. Gone.

Where does it go? Let me count some of the ways:

1. Administrative complexity - the largest single category of waste, estimated at $266 billion annually. The average physician spends the equivalent of $68,000 per year dealing with billing-related activities.³

2. Overtreatment and low-value care - procedures that deliver no clinical benefit, costing between $75 billion and $101 billion per year.²

3. Pricing failure - inflated rates for medications, payer-based services, and laboratory work, totaling $230 billion to $240 billion annually.²

4. Failure of care coordination - patients discharged without follow-up, readmitted unnecessarily, bounced between specialists who never communicate.

5. Fraud and abuse - upcoding, phantom billing, charges for services never rendered.

6. Unnecessary inpatient stays - keeping patients in hospital beds for days when the procedure required hours.

7. $4 billion hospital campuses - monuments to institutional ego that embed overhead costs into every single patient encounter.

8. Redundant diagnostic testing - the same MRI ordered by three different departments because no one shares records.

9. Prior authorization bureaucracy - clinical decisions made by insurance adjusters, not physicians, delaying care and consuming physician time.

10. Hospital-employed physician models - where a physician’s productivity is taxed at 40% to 60% by the health system overhead above them.

11. Pharmaceutical rebate games - where list prices bear no relationship to actual costs, and the spread disappears into the supply chain.

12. Defensive medicine - tests ordered to protect against litigation, not to treat the patient.

13. Supply chain opacity - hospitals paying 3x markup on devices because they lack price transparency.

14. Chronic disease management without root-cause treatment - managing downstream consequences rather than addressing lifestyle upstream.

15. EHR systems built for billing, not for care - physicians spending 2 hours on documentation for every 1 hour of patient interaction.

16. Credentialing and compliance bureaucracy - armies of administrators generating paperwork that does not improve a single patient outcome.

17. Preventable readmissions - failures of care delivery costing $102 billion to $165 billion per year,² much of it traceable to inadequate discharge planning.

18. Drug waste - hospitals discarding an estimated $3 billion in unused medications annually.

19. Executive compensation at nonprofit hospital systems - C-suite salaries that would embarrass a hedge fund, justified by “mission-driven” language.

20. The construction of $1 billion-plus inpatient facilities for elective procedures that belong in outpatient settings.

The US spends over $1,000 per capita on administrative costs alone - more than three times the OECD average of $194.⁴ Germany, our closest peer, spends $306. We spend $1,055.

The delta is not care. The delta is overhead, complexity, and institutional self-preservation.

The $4 Billion Hospital Problem

Let me address this directly, because no one in healthcare leadership will.

Henry Ford Health recently announced plans to build a new $1.8 billion hospital at its main campus in Detroit,⁵ part of a broader $2.5 billion development. They are not alone. Across the country, health systems are building flagship campuses that cost more than NFL stadiums, financed on the backs of insurance reimbursements and, ultimately, the patients and employers paying those premiums.

National average hospital construction costs have increased more than 20% over the past five years.⁶ These are not investments in better outcomes. They are investments in market share, in signaling institutional dominance, in capturing more inpatient volume for procedures that don’t require inpatient stays.

A hospital should be for life-threatening situations. Trauma. Complex cardiac surgery. Stroke. Oncology. That is what the inpatient environment is built for.

It is not built for a knee replacement. It is not built for a hip. Not for a rotator cuff. Not for a spine decompression. Not for the hundreds of elective procedures that require 90 minutes in an operating room and a few hours of recovery.

Yet patients are admitted, kept for 3 to 5 days, and billed at rates that would make the hotel industry blush - because the system is designed to maximize inpatient revenue, not to serve the patient.

530,000 Families a Year

While the health systems build billion-dollar campuses, the patients are going bankrupt.

Every year, approximately 530,000 American families file for bankruptcy due to medical bills.⁷ Medical debt is the leading cause of personal bankruptcy in the United States - a phenomenon that is virtually nonexistent in every other developed country in the world.

Almost one in five adults with healthcare debt either lose their homes or declare bankruptcy.⁸

Think about that. Not in a developing country. Here. In the wealthiest nation in human history, people are losing their homes because they had a surgery.

This is not a healthcare system. This is an extraction machine wearing a white coat.

The Blueprint Already Exists: The ASC Model

I am not here to complain. I am here to offer the proof-of-concept that the system can be redesigned.

At Indiana Orthopedic Institute, we built our model around a core operational truth: the right care, delivered in the right setting, at the right time, costs significantly less and produces better outcomes. Our ambulatory surgery center is not a compromise. It is the standard.

The data is not ambiguous. Outpatient joint replacements performed in an ASC cost 40% less than those performed in a hospital. Rotator cuff repair and knee arthroscopy cost over 50% less.⁹

A study presented at the 2024 AAOS Annual Meeting found that procedures performed at ASCs resulted in approximately 35% savings in total cost, 41% savings on facility fees, and 36% savings in Medicare payments¹⁰ - across the board, not as an outlier.

On average, the Medicare program and its beneficiaries share in more than $2.3 billion in savings each year when patients receive surgical procedures at ASCs instead of hospital outpatient departments.¹¹

The ASC model is not an experiment. It is a proven, scalable alternative to inpatient care for elective procedures - with lower infection rates, shorter recovery times, higher patient satisfaction, and dramatically reduced cost.

Why keep a patient in the hospital for 4 days for a procedure that takes 2 hours?

There is one honest answer: money. The hospital charges more. The system is built to capture that revenue. And as long as the incentives are aligned toward inpatient volume, that is where the cases will go - regardless of what is actually best for the patient.

That alignment has to end.

The Operational Directive

If you are a surgeon reading this, here is what you need to understand: the hospital will not fix this. The insurance industry will not fix this. The federal government, which has been debating healthcare reform for 40 years, will not fix this on any timeline that matters to your patients today.

You have to build the alternative yourself.

That means owning your surgical setting. It means vertically integrating your practice around patient-centered, outcomes-focused, cost-transparent care. It means refusing to be a revenue generator for a corporate system that sees your clinical autonomy as a liability.

The preventive side of this equation matters equally. We will not bend the $21 trillion curve by building more hospitals. We will bend it by addressing root causes - sleep, nutrition, exercise, metabolic health. Those conversations need to happen in every clinic, every pre-op appointment, every post-op visit. Not as an afterthought. As the core clinical mission.

I built Indiana Orthopedic Institute from two people to 100 employees and $40M in three years. Not by following the corporate playbook. By rejecting it. By building something that actually works for the patient and, by extension, for everyone who touches the system.

The $21 trillion future is not inevitable. It is a choice.

Choose differently.

What systemic waste makes you the most angry - and what are you doing about it? Let’s hear it.

- Dr. Michael Meneghini

Sources

1. Ken Research, Global Healthcare Market Outlook to 2030 (2025)

2. Shrank WH, Rogstad TL, Parekh N. “Waste in the US Health Care System: Estimated Costs and Potential for Savings.” JAMA. 2019;322(15):1501-1509.

3. Peter G. Peterson Foundation. “Almost 25% of Healthcare Spending Is Considered Wasteful.” September 2025.

4. DocBuddy. “5 Statistics on Wasteful Health Spending.” Citing OECD comparative administrative cost data, 2021.

5. Commins J. “Hospital construction slows amid rising material costs.” Modern Healthcare. May 2023.

6. Giffin S. “Hospital construction costs increase.” Health Facilities Management Magazine. January 2024.

7. Balancing Everything. “Medical Bankruptcies Statistics.” Citing American Journal of Public Health and Consumer Bankruptcy Project data. February 2024.

8. RetireGuide. “49+ U.S. Medical Bankruptcy Statistics for 2023.” March 2025.

9. OSSM Newark. “Ambulatory Surgery Centers vs. Hospital Outpatient Departments.” Citing Orthopedics Review and multiple comparative studies. October 2024.

10. Smith S, et al. “Hand and Upper Extremity Procedures Are Significantly More Cost Effective when Performed in Ambulatory Surgery Centers versus Hospital Outpatient Departments.” Presented at AAOS Annual Meeting. March 2024.

11. Advancing Surgical Care / ASC Association. “The ASC Cost Differential.” Citing University of California Berkeley Center on Health Care Markets and Consumer Welfare data.

The pandemic caused by the severe acute respiratory syndrome coronavirus 2 virus presented unprecedented challenges to elective total joint arthroplasty (TJA) services. The impact of delaying surgery cannot be understated. Consequences include the progression of pain and decrease of function, increased anti-inflammatory and pain medication use, and deteriorating mental health, as well as further bone loss and osteolysis or recurrent instability leading to soft-tissue damage. Consequently, increasing safe and effective outpatient TJA has been recommended to minimize inpatient hospital burden while appropriately caring for patients in a timely manner.

Outpatient primary TJA has been adopted at a growing number of ambulatory surgical centers (ASCs) and hospital systems in the United States. More recently, early discharge following aseptic revision TJA has been investigated; however, only a few studies have been published to date, with only 2 studies focused specifically on same-day discharge (SDD). We wanted to know if we could safely push the boundary further and bring the benefits of same-day discharge to patients requiring complex aseptic revisions and conversions.

Read more

Postoperative urinary retention (POUR) after primary hip and knee total joint arthroplasty (TJA) ranges from 4% to 46%. POUR is associated with urological injury and urinary tract infection (UTI) with possible hematogenous periprosthetic joint infection. Because of these risks, and the fact that a patient cannot be safely sent home until they can void, POUR is a common barrier to rapid-discharge TJA.

When a patient experiences POUR, the clinical team must intervene. Consequently, catheterization with an indwelling catheter, treatment with intermittent catheterization, or both are routinely used. However, the choice is driven by provider preference, with both methods associated with undesirable consequences, including increased infection risk, discomfort and pain, and compromised dignity. We wanted to look at the hard data to determine which method is actually the safest and most effective for getting our patients home.

Read more

Technological advances in the field of orthopaedics are widely being adopted across subspecialty fields in an attempt to improve the outcome of various surgical procedures. The use of robotic assistance and computer navigation during total knee arthroplasty (TKA) has increased in recent years. However, despite these proposed benefits, the literature is devoid of high quality, level-1 studies rigorously comparing manual and robotic-assisted surgery.

Furthermore, the rise of robotic-assisted TKAs has created a new environment for surgical trainees. Use of robotic assistance for TKA requires a new set of skills when compared to conventional techniques. This raises a critical question: Could the addition of robotic technology in the operating room have a negative impact on residents’ surgical skills and understanding of fundamental concepts of TKA?

Read more

Despite the clinical success of primary total knee arthroplasty (TKA) , surgical site complications (SSCs) including surgical site infections (SSIs) and wound healing complications are a leading cause of morbidity, unplanned early readmission , delayed return to work, and economic burden. This is incredibly serious, as patients with superficial SSIs are also more likely to develop deep periprosthetic joint infection (PJI) , a devastating complication.

Concurrent with the increasing number of surgeries performed in the last 2 decades, the overall medical comorbidity burden of patients undergoing primary TKA has risen dramatically , resulting in a larger total “at-risk” population. Closed incision negative pressure wound therapy (ciNPWT) is one method for reducing SSCs. However, for uncomplicated cases, surgeons should recognize the significant up-front cost difference between the 2 dressings. At our institution, the silver impregnated dressing costs $35.22, whereas a similarly sized ciNPWT dressing costs $389.99, representing a nearly 10-fold greater up-front cost per surgery.

Read more

Despite the clinical success of primary total knee arthroplasty (TKA), surgical site complications (SSCs) including surgical site infections (SSIs) and wound healing complications are a leading cause of morbidity, unplanned early readmission, delayed return to work, and economic burden. Patients with superficial SSIs are also more likely to develop deep periprosthetic joint infection (PJI), a devastating complication.

Concurrent with the increasing number of surgeries performed in the last two decades, the overall medical comorbidity burden of patients undergoing primary TKA has risen dramatically. Closed incision negative pressure wound therapy (ciNPWT) is one method for reducing SSCs. First introduced in 1997, in the form of vacuum-assisted closure, negative pressure therapy has long been considered the gold standard for treatment of acute and chronic open wounds. This technology has since been expanded to at-risk incisions in the form of ciNPWT.

However, a similarly sized ciNPWT dressing costs a hospital nearly 10 times as much as a standard occlusive silver impregnated dressing ($389.99 vs. $35.22). We wanted to know if this massive cost difference was truly justified for high-risk patients.

Read more

Periprosthetic joint infection (PJI) remains one of the most common causes of early revision total joint arthroplasty (TJA). It represents a staggering 14.8% of total hip arthroplasty (THA) and 25.5% of total knee arthroplasty (TKA) revisions performed in the United States. The financial burden is immense, with the direct costs of a single revision for infection ranging from $75,000 to $100,000.

Currently, clinical practice guidelines recommend utilizing serum tests like erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), alongside synovial tests like polymorphonuclear percentage (PMN%), to diagnose PJI. However, no single test or scoring method has been shown to be 100% sensitive and specific in diagnosing PJI. While novel biomarkers like alpha-defensin and calprotectin offer potential for increased detection, they may not be readily available at every institution and can be costly.

This has driven researchers to ask a vital question: Could a synovial marker currently utilized in the standard workup of PJI, without requiring additional infrastructure or cost, be interpreted in a novel way to predict infection?

Read more

Periprosthetic joint infection (PJI) remains one of the most common causes of early revision total joint arthroplasty (TJA), representing 14.8% of total hip arthroplasty (THA) and 25.5% of total knee arthroplasty (TKA) revisions performed in the United States. The risk of PJI after THA and TKA is approximately 0.4%-2% in the United States. Revision takes a great toll on patients, surgeons, healthcare professionals, hospitals, and the healthcare system.

Currently, no single test or scoring method has been shown to be 100% sensitive and specific in diagnosing PJI. While new biomarkers offer potential for increased detection of PJI, they may not be readily available at every institution and can be costly. Therefore, it would be ideal if a synovial marker that is currently utilized in the standard workup of PJI, without requiring additional infrastructure or cost, could be interpreted in a novel way to predict infection.

There has been growing interest in interpreting known biomarkers in a novel way to aid in diagnosing infection, including Absolute Neutrophil Count (ANC) and Neutrophil-to-Lymphocyte Ratio (NLR).

Read more

In the fast-paced world of orthopedic surgery, peer-reviewed literature is the bedrock of clinical decision-making. Surgeons rely on published studies to refine their techniques, select implants, and ultimately improve patient outcomes. However, the integrity of this process depends on relentless scrutiny and the willingness of the medical community to challenge inconsistencies.

Recently, we read a study published in The Journal of Arthroplasty with great interest. The study, entitled “Are Kinematics an Indicator of Outcome After Total Knee Arthroplasty?” by Hodge and colleagues, investigated the relationship between in vivo knee kinematics data and patient-reported outcome measures (PROMs) during specific physical tasks. We commend the authors on a certainly onerous data collection and analysis process that few investigators are willing to undertake. However, upon a deep dive into the paper, we discovered several glaring inconsistencies that compelled us to submit a formal Letter to the Editor.

Read more